Page 12 - பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் கண்டுபிடிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் கண்டுபிடிப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் கண்டுபிடிப்பு Today - Breaking & Trending Today

COVID-19 vaccine 89.3% effective in U.K. trial, less in South Africa: Novavax


COVID-19 vaccine 89.3% effective in U.K. trial but less so in South Africa, Novavax says
Sorry, but your browser needs Javascript to use this site.
If you re not sure how to activate it, please refer to this site: https://www.enable-javascript.com/
A volunteer in Novavax’s South Africa trial is examined by a doctor before receiving an injection at Wits RHI Shandukani Research Centre, in Johannesburg, in December. | JOAO SILVA / THE NEW YORK TIMES
Reuters
Jan 29, 2021
Chicago – Novavax Inc said Thursday its novel coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the country, according to a preliminary analysis. ....

New York , United States , United Kingdom , South Africa , South Africans , South African , John Moore , Amesh Adalja , Cansino Biologics , Coalition For Epidemic Preparedness Innovation , Oxford University Astrazeneca , Drug Administration , Melinda Gates Foundation , Weill Cornell Medical College , Uk Wellcome , Pfizer Inc , Johns Hopkins Center , European Union , Moderna Inc , Health Security , Novavax Inc , Professor Shabir Maddi , Epidemic Preparedness Innovation , Japan Times , Covid 19 , Covid 19 Vaccines ,

Serum Institute seeks approval to conduct trial for Novavax COVID-19 vaccine


Serum Institute seeks approval to conduct trial for Novavax COVID-19 vaccine
Last year in September, Novavax had announced its deal with Serum Institute in order to produce 2 billion doses of COVID-19 vaccines
BusinessToday.In | January 29, 2021 | Updated 16:49 IST
Novavax s protein-based coronavirus vaccine was 89.3 per cent effective in preventing coronavirus in a trial conducted in the UK
After successfully manufacturing the University of Oxford-AstraZeneca s Covishield vaccine in India, Serum Institute of India (SII) has now applied to India s drug controller to conduct a trial of Novavax Inc s COVID-19 vaccine. Serum Institute s CEO Adar Poonwalla told news agency Reuters that he is expecting a decision on the Indian trial on Novavax s vaccine soon. ....

South Africa , United Kingdom , South African , Adar Poonwalla , Coalition For Epidemic Preparedness Innovation , Melinda Gates Foundation , European Union , University Of Oxford Astrazeneca Covishield , Serum Institute , Britain Wellcome , Serum Institute Of India , Novavax Inc , Epidemic Preparedness Innovation , Wellcome Trust , Economic Survey , ஒன்றுபட்டது கிஂக்டம் , கூட்டணி க்கு பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் கண்டுபிடிப்பு , மெலிண்டா வாயில்கள் அடித்தளம் , ஐரோப்பிய தொழிற்சங்கம் , சீரம் நிறுவனம் , பிரிட்டன் வெல்கம் , சீரம் நிறுவனம் ஆஃப் இந்தியா , பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் கண்டுபிடிப்பு , வெல்கம் நம்பிக்கை , பொருளாதார கணக்கெடுப்பு ,